Nephros Inc. Initiates Pivotal U.S. Trial for OLpur(TM) H2H(TM) Hemodiafiltration Module and OLpur(TM) MD 220 Hemodiafilter

NEW YORK, NY--(Marketwire - October 16, 2007) - Nephros, Inc. (AMEX: NEP) today announced that the Company has begun the pivotal human clinical trial for its OLpur™ H2H™ Hemodiafiltration Module and OLpur™ MD 220 Hemodiafilter at the Columbia University Dialysis Center. Dr. Anthony Valeri, M.D., Associate Professor of Clinical Medicine, Columbia University, College of Physicians & Surgeons, NY is the site principal investigator. Dr. Leonard Stern, M.D., FACP, FASN, Associate Professor of Clinical Medicine at Columbia University, College of Physicians & Surgeons in New York, will act as Coordinating Principal Investigator during the trial.